This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag - Titan Pharma

BOSTON ( TheStreet) -- Welcome back to another installment of the Biotech Stock Mailbag. The first email comes from Tom S., who writes:

"Any updated thoughts on Titan Pharmaceuticals(TTNP.OB)? I follow your articles so I know where you stand on Fanapt. What are your thoughts on Probuphine and Proneura? Titan just received funding and with whatever Fanapt royalties come its way the company should be solvent for some time. I believe Titan has three full-time employees, any chance it tries to ramp up to be a viable company or is it an inevitable sale?"

For those unfamiliar, Titan, like Vanda Pharmaceuticals (VNDA - Get Report), receives a royalty payment based on sales of the schizophrenia drug Fanapt. Given my very skeptical outlook on Fanapt (see my negative comments to the next reader below) I don't see those monies amounting to much for Titan, although every little bit does help when you're as small as Titan is.

Probuphine is interesting. It's a small rod containing the opioid addiction drug buprenorphine that doctors implant just under the skin, usually in the arm. The rod slowly releases buprenorphine into a patient's bloodstream, giving a consistent steady dose of the drug for up to six months.

Probuphine works. Results from an older phase III study were published last week in Journal of the American Medical Association and Titan is working on a confirmatory, phase III study. I expect this second study to be positive too because buprenorphine is known to be effective in treating opioid addiction and the technology used in the implantable rods has been around for some time.

The issue with Probuphine is more commercial -- I think the market for the drug is very small. Nearly all opioid addicts treated with buprenorphine today take the drug orally on daily basis. Probuphine would likely only be used for those addicts who can't seem to stick with the routine of taking a daily buprenorphine pill or who constantly relapse back into their opioid or heroin addiction.

If a patient suffers side effects from the medication, the implanted rod needs to be removed, which would be a hassle and something most doctors would want to steer away from.

Very few, if any, implantable drugs have ever been commercially successful. Implantable birth control for women, for instance, was tried years ago but never caught on.

As Tom points out, Titan is a tiny, almost virtual company, so Probuphine doesn't need to be a huge success to have a meaningful impact. The ideal outcome would be for Titan to confirm the efficacy of Probuphine in the second phase III study and then sell either the drug or the entire company. Perhaps Reckitt Benckiser, which sells buprenorphine tablets under the Suboxone brand name, would want Probuphine as a smallish line extension.

The risk to this buyout thesis: Is there really anything unique about the implantable drug delivery technology that Titan brings to the table? Alternative drug delivery, whether it's implantable rods or buccal films, etc., is a bit of a commodity business these days.
1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMGN $161.10 0.00%
MELA $1.18 0.00%
VNDA $9.86 0.00%
AAPL $118.30 0.00%
FB $104.71 0.45%


Chart of I:DJI
DOW 17,719.92 -78.57 -0.44%
S&P 500 2,080.41 -9.70 -0.46%
NASDAQ 5,108.6660 -18.8590 -0.37%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs